Roberta Mazzieri

List of Publications by Year
in descending order

40 papers	5,417 citations	201385 27 h-index	329751 37 g-index
40 all docs	40 docs citations	40 times ranked	7929 citing authors

#	Article	IF	Citations
1	Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells. Cancer Cell, 2011, 19, 512-526.	7.7	543
2	Targeted genome editing in human repopulating haematopoietic stem cells. Nature, 2014, 510, 235-240.	13.7	517
3	Latent Transforming Growth Factor Î²-binding Protein 1 Interacts with Fibrillin and Is a Microfibril-associated Protein. Journal of Biological Chemistry, 2003, 278, 2750-2757.	1.6	495
4	Latent transforming growth factor-Î²: Structural features and mechanisms of activation. Kidney International, 1997, 51, 1376-1382.	2.6	459
5	Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood, 2007, 109, 5276-5285.	0.6	451
6	Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO Journal, 1997, 16, 2319-2332.	3.5	370
7	Tumor-Targeted Interferon-Î± Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis. Cancer Cell, 2008, 14, 299-311.	7.7	267
8	Vascular Endothelial Growth Factor Increases Urokinase Receptor Expression in Vascular Endothelial Cells. Journal of Biological Chemistry, 1995, 270, 9709-9716.	1.6	237
9	TGFâ€Î² Latency: Biological Significance and Mechanisms of Activation. Stem Cells, 1997, 15, 190-197.	1.4	233
10	Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor.. Journal of Cell Biology, 1991, 113, 1193-1201.	2.3	184
11	Proteolytic control of growth factor availability. Apmis, 1999, 107, 80-85.	0.9	145
12	Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance. Frontiers in Oncology, 2018, 8, 322.	1.3	137
13	Identification and Characterization of an Eight-cysteine Repeat of the Latent Transforming Growth Factor-Î² Binding Protein-1 that Mediates Bonding to the Latent Transforming Growth Factor-Î²1. Journal of Biological Chemistry, 1996, 271, 29891-29896.	1.6	128
14	Frontiers in the treatment of glioblastoma: Past, present and emerging. Advanced Drug Delivery Reviews, 2021, 171, 108-138.	6.6	125
15	Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy. Cancer Cell, 2015, 28, 225-239.	7.7	111
16	Hypomorphic Mutation of the TALE Gene Prep1 (pKnox1) Causes a Major Reduction of Pbx and Meis Proteins and a Pleiotropic Embryonic Phenotype. Molecular and Cellular Biology, 2006, 26, 5650-5662.	1.1	103
17	A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood, 2013, 122, 243-252.	0.6	102
18	Perturbation of transforming growth factor (TGF)-ÃŸ1 association with latent TGF-Î² binding protein yields inflammation and tumors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18758-18763.	3.3	95

#	Article	IF	Citations
19	Engineering a humanized bone organ model in mice to study bone metastases. Nature Protocols, 2017, 12, 639-663.	5.5	91
20	Genetic Engineering of Hematopoiesis for Targeted IFN-Î± Delivery Inhibits Breast Cancer Progression. Science Translational Medicine, 2014, 6, 217ra3.	5.8	86
21	Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy. Journal of Clinical Investigation, 2018, 128, 1971-1984.	3.9	73
22	An Uncleavable uPAR Mutant Allows Dissection of Signaling Pathways in uPA-dependent Cell Migration. Molecular Biology of the Cell, 2006, 17, 367-378.	0.9	69
23	Translational Significance for Tumor Metastasis of Tumor-Associated Macrophages and Epithelialâ€“Mesenchymal Transition. Frontiers in Immunology, 2017, 8, 1106.	2.2	69
24	Interleukinâ€23 regulates interleukinâ€17 expression in wounds, and its inhibition accelerates diabetic wound healing through the alteration of macrophage polarization. FASEB Journal, 2018, 32, 2086-2094.	0.2	45
25	The urokinase receptor and the regulation of cell proliferation. Thrombosis and Haemostasis, 2005, 93, 641-646.	1.8	38
26	Expression of truncated latent TGF-Î²-binding protein modulates TGF-Î² signaling. Journal of Cell Science, 2005, 118, 2177-2187.	1.2	38
27	Humanization of bone and bone marrow in an orthotopic site reveals new potential therapeutic targets in osteosarcoma. Biomaterials, 2018, 171, 230-246.	5.7	33
28	Facile synthesis of lactoferrin conjugated ultra small large pore silica nanoparticles for the treatment of glioblastoma. Nanoscale, 2021, 13, 16909-16922.	2.8	28
29	Immune system augmentation via humanization using stem/progenitor cells and bioengineering in a breast cancer model study. International Journal of Cancer, 2018, 143, 1470-1482.	2.3	27
30	Measurement of Active TGF-Î² Generated by Cultured Cells. , 2000, 142, 13-27.		23
31	B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity. OncoImmunology, 2018, 7, e1393599.	2.1	17
32	Engineered tumor-infiltrating macrophages as gene delivery vehicles for interferon-Î± activates immunity and inhibits breast cancer progression. OncoImmunology, 2014, 3, e28696.	2.1	16
33	A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts. Oncogene, 2007, 26, 725-732.	2.6	15
34	Urokinase and urokinase receptor expression in somatic cell hybrids. Fibrinolysis, 1994, 8, 344-352.	0.5	10
35	Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells. , 1996, 169, 300-308.		10
36	Urokinase Receptor Promotes Skin Tumor Formation by Preventing Epithelial Cell Activation of Notch1. Cancer Research, 2015, 75, 4895-4909.	0.4	9

#	Article	IF	Citations
37	Assignment of the human urokinase receptor gene (PLAUR) to 19q13. Cytogenetic and Genome Research, 1992, 60, 197-199.	0.6	7
38	Angiopoietin 2 expression in the cornea and its control of corneal neovascularisation. British Journal of Ophthalmology, 2016, 100, 1005-1010.	2.1	7
39	A novel addâ€on collimator for preclinical radiotherapy applications using a standard cell irradiator: design, construction, and validation. Medical Physics, 2020, 47, 2461-2471.	1.6	4
40	Emergence of Fc-Gamma-Riib-Dominance Contributes to Resistance to Therapeutic Antibodies in Patients with Chronic Lymphocytic Leukaemia. Blood, 2015, 126, 447-447.	0.6	0